Hovione
Hovione is a global Contract Development and Manufacturing Organization (CDMO) that specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Drug Product Intermediates. Founded in Portugal in 1959, the company has expanded to include manufacturing sites in the United States, Portugal, Ireland, China, and Macau, employing over 1,100 people. The company offers a range of services for pharmaceutical clients, focusing on bringing new and off-patent drugs to market. Hovione is known for its expertise in producing complex APIs, including highly potent compounds, and emphasizes quality, innovation, and regulatory compliance. Its product portfolio includes semi-synthetic tetracyclines, corticosteroids, and contrast agents, along with services for inhaled drugs, from API production to formulation development. Hovione serves a diverse clientele, including innovator pharmaceutical companies and generic drug manufacturers, and is committed to scientific excellence and social responsibility as a Certified B Corporation.
Work at Hovione in HR or recruiting? Claim this page
Headcount trend
Hovione went from 213 employees in Jul 2023 to 219 in Jun 2025. Last 6 months: 7 people joined, 4 left.
Org structure
Headcount by department
Hiring now
See all jobsH-1B sponsorship
The department split adds up all the years listed above. FY2026 alone: 5 filings.
Peer reviews
Worked with someone at Hovione?
Anonymous peer reviews on OffTheRecord
Similar companies
Hovione FAQ
How many employees does Hovione have?
Hovione has about 219 employees, unchanged over the last 3 months (as of Jun 2025).
Does Hovione sponsor H1B visas?
Yes. Hovione filed 5 H1B (LCA) applications in FY2026, according to the latest U.S. Department of Labor disclosures. Most of them were for Engineering roles.
What is Hovione's revenue per employee?
Hovione makes about $822K in revenue per employee, based on $180M annual revenue and 219 employees.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles. Updated 27 Nov 2025.